[Panzytopenia from combination therapy with azathioprin and allopurinol].
Azathioprine has been used in rheumatology for more than twenty years. Indications are collagen diseases with multiorgan involvement, where co-medications are frequently necessary. We describe a patient suffering from pancytopenia following a combination therapy of azathioprine and allopurinol because of lupus erythematodes and diabetic nephropathy with hyperuricemia.
Seidel
W
W
Universität Leipzig, Klinik und Poliklinik für Innere Medizin IV, Philipp-Rosenthal-Strasse 27 a, 04103 Leipzig, Germany.
D000368:Aged; D000493:Allopurinol / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood; D001379:Azathioprine / Q000009:adverse effects* / Q000627:therapeutic use; D001772:Blood Cell Count; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D004906:Erythrocyte Count; D005260:Female; D006074:Gout Suppressants / Q000009:adverse effects* / Q000627:therapeutic use; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy* / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D010198:Pancytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology
D018501:Antirheumatic Agents; D001323:Autoantibodies; D006074:Gout Suppressants; D000493:Allopurinol; D001379:Azathioprine